Cachexia is a fatal body wasting syndrome characterized by involuntary weight loss, muscle atrophy, fatigue, weakness and loss of appetite.
9 million patients diagnosed with cancer every year are affected by cachexia.
It dramatically reduces their quality of life, response and tolerance to cancer therapies and survival.
1 in 4 cancer patients dies as a consequence of cachexia and not cancer itself. Today, there is no early diagnostic method.
ImageBAT is a new CT contrast agent which enables early detection of cachexia before patients lose body weight. Detection of cachexia will be fast, pain-free and available in every hospital worldwide. ImageBAT will give millions of cancer patients an improved quality of life and a better chance to survive cancer.
We are happy to share that we have been selected to participate in the MassChallenge Switzerland 2020 accelerator program. Adiposs was one of over 1’000 other startups to apply for the accelerator located in Lausanne, Switzerland.
Adiposs is very proud to have won 150'000 CHF in the third stage of Venture Kick. This convertible loan will help Adiposs moving forward towards clinical development.
The Swiss-Indian Academia-Industry Training Camp took place last week in Switzerland after being held in India last September. Adiposs is proud to be one of the four winners of the pitching competition.
Andrej is the Chief Executive Officer and co-founder of Adiposs. He is the co-inventor of ImageBAT. Andrej has worked in the field of diagnostic imaging for over 10 years leading multidisciplinary teams and projects in academic and start-up environment. He is a co-author of 30+ scientific papers and owner of several patents in the
Andrej is the Chief Executive Officer and co-founder of Adiposs. He is the co-inventor of ImageBAT. Andrej has worked in the field of diagnostic imaging for over 10 years leading multidisciplinary teams and projects in academic and start-up environment. He is a co-author of 30+ scientific papers and owner of several patents in the fields of diagnostics, photodynamic therapy and nanotechnology.
Justyna is the Chief Operating Officer and co-founder of Adiposs. She has over 10 years of extensive business, finance and competitive intelligence experience. She has spent a big part of her professional life working at KPMG where she provided audit, advisory and due diligence services to a wide range of public and private companies in multiple jurisdictions.
Nathalie is the Chief Scientific Officer.
She has more than 8 years of experience in developing advanced pharmaceutical formulations and medical imaging agents. She is an expert in nano-sized pharmaceutical systems and also has experience in designing clinical trials.
Copyright © 2020 Adiposs , Switzerland - All Rights Reserved.